Next, we tested the therapeutic efficacy of the modified sulphamidase enzymes in ameliorating brain pathology in MPS-IIIA mice upon systemic administration using AAV2/8-TBG vectors. The gene discussed is SGSH; the disease is mucopolysaccharidosis.